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Abstract
Background: Knowledge about clinical features of critically ill patients with COVID-19 still lacks adequate information up to now.
Objectives: We aimed to describe and compare the epidemiological and clinical characteristics of critically ill patients with COVID-
19 in Rasoul Akram Hospital.
Methods: In this case series, 70 critically ill patients with COVID-19 admitted in ICU wards of Rasoul Akram Hospital, Tehran, Iran,
from 29 February to 25 April 2020 were enrolled. Demographic and clinical characteristics, laboratory data, and outcomes of the
patients were all collected and compared between deceased and recovered patients.
Results: Fifty-six cases had died of COVID-19, and 14 patients had fully recovered and discharged. The median age of the patients
was 68 years old, ranging from 22 to 91 years, 66% were men, 80% had one or more comorbidities, and hypertension was the most
common comorbidities (45% of deceased cases). The most common signs and symptoms at the onset of illness were SPO2 depression
(92%) and dyspnea (90%). Dyspnea was significantly more common in deceased patients (95%) than recovered patients (70%) (P =
0.048). Most patients had lymphopenia (80%). The number of patients who needed mechanical ventilation in the deceased patients
was 53 (95%), which was significantly more than the recovered patients (10 [70%]) (P = 0.048).
Conclusions: The mortality rate of critically ill patients with COVID-19 is very high, and the patients with dyspnea and required
mechanical ventilation are at higher risk for death.
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1. Background
In December 2019, a cluster of pneumonia cases with
an unknown cause and similar history of visiting a local
seafood market were identified in Wuhan, Hubei Province,
China, and their clinical manifestations were similar to vi-
ral pneumonia (1, 2). Deep sequencing analysis and real-
time reverse transcription PCR (RT-PCR) from lower respi-
ratory tract samples detected a new coronavirus, which
was distinct from severe acute respiratory syndrome coro-
navirus “SARS-CoV” (identity of about 79%) and Middle East
respiratory syndrome coronavirus “MERS-CoV” (identity of
about 50%) (3). The World Health Organization (WHO) of-
ficially named it Coronavirus disease-19 (COVID-19) on 11
February 2020 (4). The number of confirmed patients with
COVID-19 rapidly grew up in China and thereafter spread
throughout the world, and WHO declared COVID-19 as a
pandemic on 11 March 2020. It probably seems that COVID-
19 is the greatest threat to human societies in the 21st cen-
tury (5).
Common signs and symptoms of COVID-19 include
fever, sore throat, cough, malaise, headache, nausea, vom-
iting, diarrhea, and breathlessness (5). The clinical man-
ifestations of COVID-19 are widely heterogeneous, rang-
ing from asymptomatic infection (with no or mild pneu-
monia) to severe pneumonia with respiratory failure and
multi-organ dysfunction or death (6, 7). Unlike SARS-CoV,
patients infected with COVID-19 can transmit the disease
and contribute to the spread of infection during the pro-
dromal period with mild symptoms; therefore, the virus
spread worldwide shortly after the first detection (8). Un-
til 6 July 2020, the last update shows that over 4.5 million
cases with laboratory-confirmed with COVID-19 have been
detected in the world, and Iran is among the top 10 coun-
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tries in terms of infected patients and mortality due to
COVID-19 (9).
Since the disease has a highly contagious nature and
potential mortality (10), understanding all clinical impli-
cations of the virus will help to improve disease man-
agement, thereby controlling the pandemic. Most previ-
ous studies have just reported the general epidemiological
findings, clinical characteristics, and clinical outcomes of
patients with COVID-19 (3, 5-7), and there is a paucity of spe-
cific information about the characteristics of critically ill
patients with COVID-19.
2. Objectives
To the best of our knowledge, there is no study focus-
ing on critically ill patients infected with COVID-19 in Iran.
Therefore, this study aim at describing and comparing the
epidemiological and clinical characteristics of critically ill
patients with COVID-19 who died or survived.
3. Methods
3.1. Study Population
The present study was designed as a case series, one
which was performed on critically ill patients of COVID-19
admitted in ICU wards of Rasoul Akram Hospital, Tehran,
Iran, from 29 February to 25 April 2020. All patients with
COVID-19 enrolled in this study were diagnosed based on
the WHO interim guidance (11), and nasal and pharyngeal
swab specimens were collected for extracting SARS-CoV-2
RNA from the patients by Real-time polymerase chain re-
action (RT-PCR). According to clinical practice guidelines
from the Infectious Diseases Society of America and the
American Thoracic Society for diagnosis and treatment
of adults with community-acquired pneumonia (last up-
dated 2019) (12), critically ill patients of COVID-19 were clas-
sified for ICU care. The study protocol was approved by the
institutional review board (IRB) of Iran University of Medi-
cal Sciences, and the Ethics Committee approved the study
before its initiation (ethics code: IR.IUMS.REC.1399.037).
3.2. Data Collection
Demographic and clinical characteristics and labora-
tory data of the patients, including age, gender, smoking
history, comorbidities, clinical signs and symptoms, his-
tory of annual influenza vaccination, mechanical ventila-
tion, hemodynamic status, peripheral capillary oxygen sat-
uration (SPO2), complete blood count (CBC), lactate dehy-
drogenase (LDH), D-dimer, and Arterial blood gas (ABG)
were obtained from their medical records upon admission
using a standardized data collection form. Moreover, pa-
tients’ outcomes (death or survival) were extracted from
medical records.
3.3. Statistical Analysis
The statistical software package SPSS for Windows, ver-
sion 20.0 (SPSS, Chicago, IL, USA) was used for data anal-
ysis. Descriptive analyses of the variables were expressed
as mean ( ± standard deviation = SD), median (with an in-
terquartile range = IQR = Q1-Q3), or number (%). The clini-
cal characteristics of both groups (death or Survival) were
compared using χ2 tests or Fisher’s exact test for propor-
tions and unpaired t-tests for means. Pearson correlation
coefficient was calculated to evaluate the association be-
tween characteristics in each group. A P value of < 0.05 was
considered statistically significant.
4. Results
From 29 February to 25 April 2020, the number of 70
critically ill patients with laboratory-confirmed COVID-19
was admitted to the ICU of Rasoul Akram Hospital. Over-
all, 56 cases had died of COVID-19, and 14 patients had fully
recovered and been discharged. The median age of the pa-
tients was 68 years old (IQR = 57·0 - 77·0), ranging from 22
to 91 years. Gender distribution (male/female) of deceased
and recovered patients was 36/20 and 10/4, respectively (P
= 1.00). Fifty-six patients (80%) had one or more comorbidi-
ties, and hypertension was the most common comorbidi-
ties between them, 50% of infected patients and 45% of de-
ceased cases had hypertension. History of cigarette smok-
ing was more predominant in deceased patients (11; 20%)
than in recovered patients (0; 0%); however, its difference
was not statistically significant (P = 0.184). The baseline
characteristics of the patients are represented in Table 1.
There were no statistically significant differences between
deceased and recovered patients regarding baselines.
Overall, the most common signs and symptoms at the
onset of illness were SPO2 saturation drop (64 [92%]), dys-
pnea (63 [90%]), followed by cough (56 [80%]), and fever
(56 [80%]); less common signs and symptoms were myal-
gia (29 [42%]), sore throat (11 [16%]), diarrhea (8 [12%]), and
nausea and vomiting (6 [8%]). Dyspnea was significantly
more common in non-survivors 53 (95%) compared with
recovered patients 10 (70%) (P = 0.048). We found cough
and fever in 77.5% of non-survivors compared with 90% in
recovered patients (P = 0.66). However, there were no sta-
tistically significant differences between survivor and non-
survivor regarding other signs and symptoms at the onset
of illness (Table 2).
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Table 1. Baseline Characteristics of Critically Ill Patients with COVID-19a
Baseline Characteristics Total Recovered Patients (N =
14)
Deaths (N = 56) P Value
Age 66.22 ± 14.36 71.10 ± 11.79 65.00 ± 14.820 0.234
Gender 1.000
Female 24 (34) 4 (30.0) 20 (35.0)
Male 46 (66) 10 (70.0) 36 (65.0)
Hypertension 0.289
No 35 (50) 4 (30.0) 31 (55.0)
Yes 35 (50) 10 (70.0) 25 (45.0)
Asthma 1.000
No 65 (94) 14 (100.0) 51 (92.5)
Yes 5 (6) 0 (0.0) 5 (7.5)
Diabetes 1.000
No 41 (58) 9 (60.0) 32 (57.5)
Yes 29 (42) 5 (40.0) 25 (42.5)
Chronic heart failure 1.000
No 60 (86) 12 (90.0) 48 (85.0)
Yes 10 (14) 2 (10.0) 8 (15.0)
Smoking history 0.184
No 59 (84) 14 (100) 45 (80)
Yes 11 (16) 0 (0) 11 (20)
Received annual influenza vaccine 0.327
No 62 (88) 14 (100.0) 48 (85.0)
Yes 8 (12) 0 (0.0) 8 (15.0)
aValues are expressed as No. (%) or mean ± SD.
The median duration of fever was 12 and 13 days in sur-
vivors and non-survivors, respectively. The median dura-
tion of cough persisted for 16 days and 13 days in survivors
and non-survivors, respectively. Seven (50%) survivors still
had a cough on discharge. Moreover, 95% of non-survivors
and 70% of survivors were intubated (P = 0.048). Among
the deceased patients, the median time from hospital ad-
mission to mechanical ventilation was 3.8 days, which was
similar to recovered patients (4.2 days). The median time
of ICU stay was 10 days for non-survivors and 6.5 days for
survivors. The median time of invasive mechanical venti-
lation need in ICU was 6.5 and 4 days for deceased and sur-
vived patients, respectively (P ≥ 0.05).
Among non-survivors, the median time from illness
onset was 9, 10, and 11 days to sepsis, ARDS, and secondary
infection, respectively. Among survivors, two cases of sec-
ondary infection and acute kidney injury were observed,
which occurred 7 and 10 days after illness onset, respec-
tively.
Clinical and laboratory findings of the patients were
recorded on the day of hospital admission for all patients
(Table 3). The blood counts of patients on hospital admis-
sion showed that only 17/70 patients had anemia. Most of
them had lymphopenia (lymphocyte count < 1.0 × 109/L;
56 (80%) patients); however, it was not significant between
the two groups. The mean LDH levels on admission were
higher in the deceased (1.073.68 ± 293.50) than the recov-
ered patients (970.60± 205.98), but the difference was not
significant (P = 0.519). All of the patients had D-dimer ≥
0.5 (P = 0.00). Hemodynamic instability (need to receive
vasopressor on admission) was recorded in 3 (5%) of de-
ceased patients, while all of the recovered patients had sta-
ble hemodynamic on the time of hospital admission. In
addition, the mean of peripheral oxygen saturation (SpO2)
in deceased patients was 62.80 ± 12.68, which was slightly
lower than that of recovered patients (70.14 ± 8.37).
The Pearson correlations of SPO2 with Pco2, Pao2, PH,
duration of mechanical ventilation, and respiratory rate
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Table 2. Signs and Symptoms Upon Hospital Admission of Critically Ill Patients with COVID-19 Infectiona
Signs and Symptoms Upon Hospital
Admission
Total Recovered Patients (N =
14)
Deaths (N = 56) P Value
Fever 0.663
No 14 (20) 2 (10.0) 12 (22.5)
Yes 56 (80) 12 (90.0) 44 (77.5)
Dyspnea 0.048
No 7 (10) 4 (30.0) 3 (5.0)
Yes 63 (90) 10 (70.0) 53 (95.0)
SPO2 < 93% 1.000
No 6 (8) 2 (10.0) 4 (7.5)
Yes 64 (92) 12 (90.0) 52 (92.5)
Myalgia or fatigue 0.488
No 41 (58) 10 (70.0) 31 (55.0)
Yes 29 (42) 4 (30.0) 25 (45.0)
Nausea and vomiting 0.571
No 64 (92) 14 (100.0) 50 (90.0)
Yes 6 (8) 0 (0.0) 6 (10.0)
Cough 0.663
No 14 (20) 2 (10.0) 12 (22.5)
Yes 56 (80) 12 (90.0) 44 (77.5)
Diarrhea 0.327
No 62 (88) 14 (100.0) 48 (85.0)
Yes 8 (12) 0 (0.0) 8 (15.0)
Sore throat 1.000
No 59 (84) 11 (80.0) 48 (82.5)
Yes 11 (16) 3 (20.0) 8 (17.5)
aValues are expressed as No. (%).
was tested for deceased and recovered patients and the re-
sults of which are shown in Table 4. In the recovered group,
no significant relationship was found between these vari-
ables (P > 0.05). In the deceased group, there is an inverse
relationship only between SPO2 with respiratory rate (r = -
0.326, P = 0.040), whereas the relationship between other
variables with SPO2 was not significant (P > 0.05).
5. Discussion
The mainstay of treatment for COVID-19 is supportive
care to control symptoms and protects important organs
due to lack of vaccine and specific antiviral medication for
effective treatment at this time. It seems that close follow-
up and supportive care are sufficient to manage the dis-
ease, but aggressive treatments and intensive care units for
critically ill patients are needed (13). Up to now, limited
studies have specifically focused on critically ill patients
with COVID-19, and all three previously published studies
of critically ill patients had a small sample size (14-16). In
the present study, we report clinical features and outcomes
of 70 critically ill patients with confirmed COVID-19 who ad-
mitted to ICU.
In agreement with the previous reports, 66% of critical
cases infected by COVID-19 were men. In the Chinese cohort
study (14), nearly 70% of critically ill patients were men,
and it was 63% in the American study (16). Based on pieces
of evidence, male patients are more susceptible to COVID-
19 and seem to be the most prone to severe conditions.
Our results showed these findings as well. However, there
is no significant difference between survivors and non-
survivors regarding gender distribution. As mentioned
in previous studies, a large proportion of patients (80%)
had one or more comorbidities, and hypertension was the
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Table 3. Clinical and Laboratory Findings of Critically Ill Patients with COVID-19a
Clinical and Laboratory Findings Total Recovered Patients (N =
14)
Deaths (N = 56) P Value
Lymphopenia 1.000
No 14 (20) 3 (20.0) 11 (20.0)
Yes 56 (80) 11 (80.0) 45 (80.0)
Anemia 1.000
No 53 (76) 11 (80.0) 42 (75.0)
Yes 17 (24) 3 (20.0) 14 (25.0)
Hemodynamic instability 1.000
No 67 (96) 14 (100.0) 53 (95.0)
Yes 3 (4) 0 (0.0) 3 (5.0)
Required mechanical ventilation 0.048
No 7 (10) 4 (30) 3 (5)
Yes 63 (90) 10 (70) 53 (95)
Days from hospital admission to
mechanical ventilation need, median
4 4.2 3.8 0.555
Days of ICU stay, median 8.2 6.5 10 0.541
Days of invasive mechanical
ventilation need in ICU, median
5.2 4 6.5 0.450
LDH, U/L 1053.06 ± 279.44 970.60 ± 205.98 1073.68 ± 293.50 0.519
D-dimer, µg/L ≥ 0.5 ≥ 0.5 (100%) ≥ 0.5 (100%) 0.00
SPO2 , % 63.89 ± 12.34 70.14 ± 8.37 62.80 ± 12.68 0.236
Pao2 , mmHg 35.71 ± 11.87 34.85 ± 9.06 35.86 ± 12.38 0.839
Pco2 , mmHg 49.74 ± 11.87 50.43 ± 7.87 49.63 ± 23.49 0.399
pH 7.34 ± 0.10 7.39 ± 0.04 7.33 ± 0.10 0.294
aValues are expressed as No. (%) or mean ± SD.
most common comorbidity between the patients (17). We
found hypertension as the most prevalent comorbidity as
well. Moreover, we noted that the rate of comorbidities did
not differ between survivors and non-survivors.
The mortality rate in our study was 80% that was
higher than the previous studies. In an American study,
the mortality rate was 50% (16), and it was 61.5% in a chines
study regarding critically ill patients (15). Both mentioned
studies followed the patients for 14 and 28 days, and some
patients remained in ICU or intubated at the time of data
gathering.
Clinical characteristics of COVID-19 are nearly similar
to previous coronavirus infections. In our study, SPO2 de-
cline, dyspnea, cough, and fever were the most common
symptoms in the time of admission in critically ill patients
with COVID-19. Consistent with our results, other stud-
ies reported that these symptoms are the most common
among critical patients with COVID-19 pneumonia (17).
Moreover, similar to previous studies, intestinal signs and
symptoms were less common (diarrhea 12%, nausea, and
vomiting 8%) among the patients of our study, whereas in-
testinal signs and symptoms have been presented in about
20% - 25% of patients with MERS-CoV or SARS-CoV infection
(18, 19). Comparing non-survivors with survivors in the cur-
rent study, dyspnea was significantly more common in de-
ceased patients; however, other prevalent symptoms were
similar in both deceased and recovered patients.
According to laboratory tests, lymphopenia was seen
in 80% of critically ill patients, and it was concordant with
the results from the previous studies. However, there is
no difference between survivors and deaths. This is consis-
tent with the report of Yang et al. (14), who showed that
more than 80% of critically ill patients had lymphopenia,
and it was 75% in case series done in the USA (16). Lym-
phopenia is a common characteristic of critically ill pa-
tients with SARS-CoV infection because SARS-CoV viral par-
ticles play a destructive role in damaging the cytoplasmic
component of the lymphocytes (20). In addition, owing
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Table 4. Correlation Between SPO2 and Pco2 , Pao2 , LDH, PH, Respiratory Rate, and Duration of Mechanical Ventilation Based on Survivors and Non-Survivors
Characteristics
Correlations








0.613 0.446 0.321 0.240 0.280 0.356
P value 0.143 0.316 0.483 0.605 0.543 0.434





-0.005 0.292a -0.094 -0.032 0.280a -0.326b
P value 0.976 0.068 0.562 0.844 0.080 0.040
Numbers 56 56 56 56 56 56
aCorrelation is significant at 0.01 level (2-tailed).
bCorrelation is significant at 0.05 level (2-tailed).
to the induced apoptosis of lymphocytes by the MERS-CoV
virus, lymphopenia is a prominent feature in critically ill
patients with MERS infection (21, 22). Therefore, it cre-
ates a hypothesis that lymphopenia in critically ill patients
with COVID-19 could be caused by virus-induced necrosis
or apoptosis in lymphocytes. In a previous study, which re-
ported the characteristics of non-critical patients infected
with COVID-19, only 35% of patients had mild lymphopenia
(23), suggesting that the severity of lymphopenia may the
probable reason for the severity of COVID-19.
Mechanical ventilation plays an essential role as a sup-
portive treatment for critically ill patients. In our study,
most of the patients (90%) needed mechanical ventilation.
This finding was along with the results of other studies. In
the study conducted by Arentz et al. (15), 71% of critically
ill patients needed mechanical ventilation, and it was 75%
in another study by Bhatraju et al. (16). Additionally, the
rate of required mechanical ventilation in non-survivors
was significantly more than the recovered. This is similar
to Yang et al. (14), who showed that 57% of non-survivors re-
quired mechanical ventilation, but it was 35% among sur-
vivors.
There were a number of limiting factors, diminishing
the impact of results of which the patient population in
a single referral center is the most important one. Thus
our results may not be representative of patients in Iran
with this condition due to the retrospective study design,
not all laboratory tests were done in all patients, including
procalcitonin, IL-6, and serum ferritin. Also, since we are
involved in the management of critically ill patients with
COVID-19 in one hospital, our sample size was small. In
addition, some specific information from the ICU, includ-
ing mechanical ventilation settings, radiological findings,
and supportive treatments and interventions, are missed.
Instead, we hope that our efforts will encourage a larger
and multicenter investigation for a better understanding
of clinical features, risk factors, and outcomes of COVID-19.
5.1. Conclusions
Our findings provide some important clinical charac-
teristics of critically ill patients with COVID-19 admitted
to ICU and needed ICU care and ventilatory support. The
mortality rate of critically ill patients with COVID-19 is very
high, and the patients with dyspnea and required mechan-
ical ventilation are at higher risk for poor outcomes and
death after ICU admission. We found that male hyperten-
sive gender with dyspnea at admission were risk factors
for ICU-admission of adult patients with COVID-19. How-
ever, more extensive large multicenter studies should be
performed to define all risk factors and specify more effec-
tive care for these challenging patients.
Acknowledgments
The authors wish to thank Rasoul Akram Hospital Clini-
cal Research Development Center (RCRDC), Iran University
of Medical Science, for technically supported implementa-
tion of the project.
6 Anesth Pain Med. 2020; 10(5):e107211.
Rahimzadeh P et al.
Footnotes
Authors’ Contribution: All authors agree to be account-
able for all aspects of the work in ensuring that questions
related to the accuracy or integrity of any part of the work
are appropriately investigated and resolved. Study con-
cept and design: PR. Acquisition of data: SHRF, SA, and AH.
Drafting the manuscript: PR and RF. Critical revision of the
manuscript for important intellectual content: SHE. Study
supervision: PR and SHRF.
Conflict of Interests: The authors have no conflict of in-
terest to declare.
Ethical Approval: The study protocol was approved
by the institutional review board (IRB) of Iran Uni-
versity of Medical Sciences, and the Ethics Committee
approved the study before its initiation (ethics code:
IR.IUMS.REC.1399.037).
Funding/Support: It was not declared by the authors.
Informed Consent: Informed consent was obtained from
all individuals.
References
1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coron-
avirus from patients with pneumonia in China, 2019. N Engl J Med.
2020;382(8):727–33. doi: 10.1056/NEJMoa2001017. [PubMed: 31978945].
[PubMed Central: PMC7092803].
2. Gralinski LE, Menachery VD. Return of the coronavirus: 2019-
nCoV. Viruses. 2020;12(2). doi: 10.3390/v12020135. [PubMed: 31991541].
[PubMed Central: PMC7077245].
3. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation
and epidemiology of 2019 novel coronavirus: Implications for virus
origins and receptor binding. TheLancet. 2020;395(10224):565–74. doi:
10.1016/s0140-6736(20)30251-8.
4. World Health Organization. Naming the coronavirus disease (COVID-19)
and the virus that causes it. WHO; 2020.
5. Wu Z, McGoogan JM. Characteristics of and important lessons
from the coronavirus disease 2019 (COVID-19) outbreak in China:
Summary of a report of 72314 cases from the Chinese Center for
Disease Control and Prevention. JAMA. 2020;323(13):1239–42. doi:
10.1001/jama.2020.2648. [PubMed: 32091533].
6. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular sys-
tem. Nat Rev Cardiol. 2020;17(5):259–60. doi: 10.1038/s41569-020-0360-
5. [PubMed: 32139904].
7. Chan JFW, Yuan S, Kok KH, To KKW, Chu H, Yang J, et al. A familial clus-
ter of pneumonia associated with the 2019 novel coronavirus indicat-
ing person-to-person transmission: A study of a family cluster. Lancet.
2020;395(10223):514–23. doi: 10.1016/s0140-6736(20)30154-9.
8. Alimohamadi Y, Taghdir M, Sepandi M. Estimate of the basic repro-
duction number for COVID-19: A systematic review and meta-analysis.
J Prev Med Public Health. 2020;53(3):151–7. doi: 10.3961/jpmph.20.076.
[PubMed: 32498136].
9. Worldometers. Irandemographics. 2020. Available from: https://www.
worldometers.info/world-population/iran-population/.
10. Yeo C, Kaushal S, Yeo D. Enteric involvement of coronaviruses: Is
faecal-oral transmission of SARS-CoV-2 possible? Lancet Gastroen-
terol Hepatol. 2020;5(4):335–7. doi: 10.1016/s2468-1253(20)30048-0.
[PubMed: 32087098]. [PubMed Central: PMC7130008].
11. WHO. Clinical management of severe acute respiratory infec-
tion when Novel coronavirus (nCoV) infection is suspected: In-




12. Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al.
Diagnosis and Treatment of Adults with Community-acquired Pneu-
monia. An Official Clinical Practice Guideline of the American Tho-
racic Society and Infectious Diseases Society of America. Am J Respir
Crit Care Med. 2019;200(7):e45–67. doi: 10.1164/rccm.201908-1581ST.
[PubMed: 31573350]. [PubMed Central: PMC6812437].
13. Murthy S, Gomersall CD, Fowler RA. Care for critically Ill patients with
COVID-19. Jama. 2020;323(15). doi: 10.1001/jama.2020.3633. [PubMed:
32159735].
14. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and out-
comes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan,
China: A single-centered, retrospective, observational study. Lancet
Respir Med. 2020;8(5):475–81. doi: 10.1016/s2213-2600(20)30079-5.
15. Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M, et
al. Characteristics and outcomes of 21 critically Ill patients with
COVID-19 in Washington State. Jama. 2020;323(16):1612–4. doi:
10.1001/jama.2020.4326. [PubMed: 32191259]. [PubMed Central:
PMC7082763].
16. Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR, Nalla AK,
et al. Covid-19 in critically Ill patients in the Seattle Region - case se-
ries. N Engl J Med. 2020;382(21):2012–22. doi: 10.1056/NEJMoa2004500.
[PubMed: 32227758]. [PubMed Central: PMC7143164].
17. Fu L, Wang B, Yuan T, Chen X, Ao Y, Fitzpatrick T, et al. Clini-
cal characteristics of coronavirus disease 2019 (COVID-19) in China:
A systematic review and meta-analysis. J Infect. 2020;80(6):656–65.
doi: 10.1016/j.jinf.2020.03.041. [PubMed: 32283155]. [PubMed Central:
PMC7151416].
18. Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, Al-Rabiah FA, Al-Hajjar S, Al-Barrak
A, et al. Epidemiological, demographic, and clinical characteristics
of 47 cases of Middle East respiratory syndrome coronavirus disease
from Saudi Arabia: A descriptive study. Lancet InfectDis. 2013;13(9):752–
61. doi: 10.1016/s1473-3099(13)70204-4. [PubMed: 23891402]. [PubMed
Central: PMC7185445].
19. Lee N, Hui D, Wu A, Chan P, Cameron P, Joynt GM, et al. A major out-
break of severe acute respiratory syndrome in Hong Kong. N Engl
J Med. 2003;348(20):1986–94. doi: 10.1056/NEJMoa030685. [PubMed:
12682352].
20. Gu J, Gong E, Zhang B, Zheng J, Gao Z, Zhong Y, et al. Multiple organ
infection and the pathogenesis of SARS. J Exp Med. 2005;202(3):415–
24. doi: 10.1084/jem.20050828. [PubMed: 16043521]. [PubMed Central:
PMC2213088].
21. Chu H, Zhou J, Wong BH, Li C, Chan JF, Cheng ZS, et al. Middle east
respiratory syndrome coronavirus efficiently infects human primary
t lymphocytes and activates the extrinsic and intrinsic apoptosis
pathways. J Infect Dis. 2016;213(6):904–14. doi: 10.1093/infdis/jiv380.
[PubMed: 26203058]. [PubMed Central: PMC7107330].
22. Liu WJ, Zhao M, Liu K, Xu K, Wong G, Tan W, et al. T-cell immunity
of SARS-CoV: Implications for vaccine development against MERS-
CoV. Antiviral Res. 2017;137:82–92. doi: 10.1016/j.antiviral.2016.11.006.
[PubMed: 27840203]. [PubMed Central: PMC7113894].
23. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemio-
logical and clinical characteristics of 99 cases of 2019 novel coro-
navirus pneumonia in Wuhan, China: A descriptive study. Lancet.
2020;395(10223):507–13. doi: 10.1016/s0140-6736(20)30211-7. [PubMed:
32007143]. [PubMed Central: PMC7135076].
Anesth Pain Med. 2020; 10(5):e107211. 7
